Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Receivables (2016 - 2025)

Amphastar Pharmaceuticals has reported Receivables over the past 13 years, most recently at $143.6 million for Q4 2025.

  • Quarterly results put Receivables at $143.6 million for Q4 2025, up 5.33% from a year ago — trailing twelve months through Dec 2025 was $143.6 million (up 5.33% YoY), and the annual figure for FY2025 was $143.6 million, up 5.33%.
  • Receivables for Q4 2025 was $143.6 million at Amphastar Pharmaceuticals, down from $147.3 million in the prior quarter.
  • Over the last five years, Receivables for AMPH hit a ceiling of $147.3 million in Q3 2025 and a floor of $67.9 million in Q2 2021.
  • Median Receivables over the past 5 years was $109.8 million (2023), compared with a mean of $109.0 million.
  • Biggest five-year swings in Receivables: decreased 6.12% in 2022 and later soared 53.93% in 2023.
  • Amphastar Pharmaceuticals' Receivables stood at $78.8 million in 2021, then increased by 12.69% to $88.8 million in 2022, then grew by 29.43% to $114.9 million in 2023, then grew by 18.57% to $136.3 million in 2024, then rose by 5.33% to $143.6 million in 2025.
  • The last three reported values for Receivables were $143.6 million (Q4 2025), $147.3 million (Q3 2025), and $133.0 million (Q2 2025) per Business Quant data.